Ultragenyx Pharmaceutical Inc.
RAREHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, Ultragenyx Pharmaceutical Inc. (RARE) is listed under Biotechnology. Valued at $1.51B, RARE is a small-cap name in its sector. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Market Cap
$1.51B
Beta
0.32
P/E (TTM)
—
P/E (Fwd)
75.82
EPS (TTM)
$-5.83
EPS (Fwd)
$0.20
ROE
—
ROA
-24.2%
Cash
$292.0M
Total Debt
$1.20B
Free CF
-$221.8M
52W Change
-51.4%
Annual Financials
Cash vs Debt
Where RARE stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, RARE finished 0.92% above its 150-day moving average ($24.98) and 3.93% below its 200-day moving average ($26.24). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RARE overbought or oversold?
At the September 1, 2026 close, RARE's RSI(14) was 35.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, RARE has $292.0M in cash with $1.20B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$221.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $363.3M (2022) to $673.0M (2025), reflecting a 85% increase over the period.
With a beta below 0.7, Ultragenyx Pharmaceutical Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing RARE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.